Biomatrix, Roche Holding Ltd. deal

BIOX reacquired the European rights to Synvisc, its osteoarthritis treatment for the knee, from Roche.

Under the revised agreement, BIOX will receive $3 million from Roche. The pharma company, with 355,000 shares of BIOX, also will retain its 3.5 percent equity position in the company. To date, Roche has paid BIOX $1 million. ...